Pfizer (PFE) Cost of Revenue (2009 - 2026)
Pfizer (PFE) posted quarterly Cost of Revenue of $3.5 billion for Q1 2026, up 24.71% year-over-year from $2.8 billion in Q1 2025, and down 32.7% quarter-over-quarter from $5.3 billion in Q4 2025.
Pfizer (PFE) Cost of Revenue (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Cost of Revenue for 18 consecutive years, with $3.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue rose 24.71% year-over-year to $3.5 billion; the TTM figure through Mar 2026 stood at $16.8 billion (down 21.88% YoY), while the FY2025 annual figure was $16.1 billion, down 9.99% from the prior year.
- Cost of Revenue fell to $3.5 billion in Q1 2026 per PFE's latest filing, from $5.3 billion in the prior quarter.
- Across five years, Cost of Revenue topped out at $11.9 billion in Q3 2024 and bottomed at $2.8 billion in Q1 2025.
- Historically, Cost of Revenue has averaged $5.6 billion across 5 years, with a median of $4.2 billion in 2025.
- Annual changes were most pronounced in 2022 — Cost of Revenue jumped 140.17% — and 2025, when it plunged 65.06%.
- Pfizer's Cost of Revenue stood at $8.6 billion in 2022, then slipped by 12.55% to $7.6 billion in 2023, then soared by 57.9% to $11.9 billion in 2024, then tumbled by 55.85% to $5.3 billion in 2025, then sank by 32.7% to $3.5 billion in 2026.
- Business Quant data shows PFE's Cost of Revenue at $3.5 billion in Q1 2026, $5.3 billion in Q4 2025, and $4.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 8.05 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 4.29 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 4.40 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 3.71 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.52 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.81 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.58 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 4.09 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 3.04 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 3.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 4.09 Bn |
| Jun 28, 2026 | 4.09 Bn |
| Mar 29, 2026 | 3.55 Bn |
| Mar 29, 2026 | 3.55 Bn |
| Dec 31, 2025 | 5.27 Bn |
| Dec 31, 2025 | 5.27 Bn |
| Sep 28, 2025 | 4.17 Bn |
| Sep 28, 2025 | 4.17 Bn |
| Jun 29, 2025 | 3.78 Bn |
| Jun 29, 2025 | 3.78 Bn |
| Mar 30, 2025 | 2.85 Bn |
| Mar 30, 2025 | 2.85 Bn |
| Sep 29, 2024 | 11.94 Bn |
| Sep 29, 2024 | 11.94 Bn |
| Jun 30, 2024 | 3.30 Bn |
| Jun 30, 2024 | 3.30 Bn |
| Mar 31, 2024 | 3.38 Bn |
| Mar 31, 2024 | 3.38 Bn |
| Dec 31, 2023 | 7.56 Bn |
| Dec 31, 2023 | 7.56 Bn |